A Phase 3 interventional study of Lacosamide and Placebo in Bipolar Affective Disorder, sponsored by University of Sao Paulo. Recruiting at 1 site in Brazil. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-20.
Sponsored by University of Sao Paulo · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Bipolar Disorder by University of Sao Paulo — 3 open to participants now, 4 under way, 1 of them phase 3. Bipolar Disorder · University of Sao Paulo.
Among the 15 studies in Bipolar Disorder by University of Sao Paulo, this one is the 11th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2026, is the only one in phase 3, and was the 14th registered.
1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.
Browse Bipolar Disorder studies →3 of the 15 studies in Bipolar Disorder by University of Sao Paulo are open now, in 1 country. Recruiting first, the newest first:
University of Sao Paulo · Sites in Brazil
Ages 18–65
University of Sao Paulo · Sites in Brazil
Ages 18–60
By country, each count listing its studies:
Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 3 · Phase 4 1
First in 2010; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 64 across 1,282 interventional studies indexed under Bipolar Disorder.
Median enrollment 60 across the 13 interventional studies, 130 across the 2 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Sao Paulo is the lead sponsor of 1,036 studies on the registry; 96 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
3 of the studies in Bipolar Disorder by University of Sao Paulo that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07412132Phase 3University of Sao PauloEvaluation of the Efficacy, Safety, and Tolerability of Lacosamide in Major Depressive Episodes of Bipolar Disorder Types I and II. | 2027-01 |
| NCT06488573University of Sao PauloPROgram To Enhance Cardiovascular Risk Trough an Intervention of Nutrition in Bipolar Disorder | 2026-11 |
| NCT07472920University of Sao PauloEmpagliflozin Adjunctive Therapy in Bipolar Depression | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies in Bipolar Disorder by University of Sao Paulo, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Initially, observational studies suggested a possible effect of Lacosamide on depressive and anxious symptoms in individuals with epilepsy, and later, an open-label study demonstrated the efficacy of lacosamide in improving depressive and manic symptoms in individuals with bipolar disorder (BD). The primary objective of this study is to evaluate the efficacy of combining lacosamide as an augmentation treatment to first- or second-line medication treatments in moderate to severe major depressive episodes of treatment-resistant BD I and II (failure of at least two adequate treatments during the current episode). The main hypothesis of the study is that lacosamide produces a greater reduction in depression scores compared to a placebo treatment and that both groups will exhibit similar rates of side effects and adverse events. We will conduct a double-blind, randomized, parallel-group pilot study, comparing the enhancement of the treatment that patients had been using with lacosamide and placebo, over a duration of 12 weeks. Forty subjects aged between 18 and 65 years with a diagnosis of BD (I or II) in a moderate or severe major depressive episode, despite the use of first- or second-line treatments, will be selected. The primary outcome will be the assessment of lacosamide efficacy through the difference in scores on the Hamilton Depression Rating Scale (HAMD-17) from the initial visit to the end of week 12 of intervention between the lacosamide and placebo groups.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Lacosamide 50mg twice a day
Drug: Lacosamide
Drug: Placebo
Lacosamide 50mg will be give twice a day por 2 weeks, then Lacosamide 100mg twice a day until the end of the study.
Placebo tablets are similar in its features to the active drug, but without any pharmacological agent inside.
Primary outcome
The efficacy of lacosamide assessed by the difference in Hamilton Depression Scale score from the initial visit to the end of week 12 of the intervention between the lacosamide and placebo groups. Minimum: 0 point Maximum: 50 points. The increase in the pontuation of the scale is related to worse outcomes.
Time frame: week 12
Secondary Outcome
Difference in response rates (50% or more reduction) assessed by the Hamilton Depression Scale from the initial visit to the end of week 12 of intervention, between the lacosamide and placebo groups;
Time frame: week 12
Secondary outcome
Difference in response rates (50% or more reduction) assessed by the Montgomery-Asberg Depression Rate Scale from the initial visit to the end of week 12 of intervention, between the lacosamide and placebo groups;
Time frame: week 12
Secondary outcome
Difference in remission rates (\< 7 points) assessed by the Hamilton Depression Scale from the initial visit to the end of week 12 of intervention, between the lacosamide and placebo groups;
Time frame: week 12
Secondary outcome
Difference in remission rates (\<11 points) assessed by the Montgomery-Asberg Depression Rate Scale from the initial visit to the end of week 12 of intervention, between the lacosamide and placebo groups;
Time frame: week 12
Secondary outcome
Difference in side effects from the initial visit to the end of week 12 of intervention, between the lacosamide and placebo groups;
Time frame: week 12
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Jan 2027, 12 months after the start.
Of 43 phase 3 interventional studies under Bipolar Disorder, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 60. This study's planned 12 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lacosamide